Rein Therapeutics, Inc. · NASDAQ:RNTX

Rein Therapeutics — Aileron Therapeutics — Corporate Update (June 2020)

6 slides from Rein Therapeutics's corporate update, Jun 1, 2020

  1. Slide 1: Interim data from Phase 1b dose optimization trial

    Interim data from Phase 1b dose optimization trial Exhibit 99.1

  2. Slide 2: ALRN-6924: Ongoing Ph1b Clinical Trial in Small Cell Lung Cancer Patients Receiving Topotecan

    ALRN-6924: Ongoing Ph1b Clinical Trial in Small Cell Lung Cancer Patients Receiving Topotecan Dose Optimization N = 18 ALRN-6924 24h before topotecan 3 dose levels tested Expansion commenced Schedule Optimization N = 20 ALRN-6924 6h before topotecan Test up to 2 dose levels Start enrollment planned

  3. Slide 3: Demographics and Key Baseline Characteristics

    Demographics and Key Baseline Characteristics Data cutoff for interim analysis of the dose optimization part of the trial 5/13/2020; 3 patients on-going 0.3 mg/kg N (%) N=6 0.6 mg/kg N (%) N=5 1.2 mg/kg N (%) N=6 Total N (%) N=17 Age Median 69.5 67 58 65 Mean 66 64.4 59.5 63.2 Gender Male 6 (100) 2

  4. Slide 4: Study Drug Exposure

    Study Drug Exposure 0.3 mg/kg N=6 0.6 mg/kg N=5 1.2 mg/kg N=6 Total N=17 Duration of exposure (days) Mean (SD) 49 41 61 51 Median (Min, Max) 31 (6, 103) 27 (6, 90) 42 (27, 157) 28 (6, 157) Number of cycles completed Mean (SD) 2.8 2 3.3 2.8 Median (Min, Max) 2 (1, 5) 1 (1, 4) 2.5 (1, 8) 2 (1, 8) Topo

  5. Slide 5: Safety: Key Adverse Events (AEs)

    Safety: Key Adverse Events (AEs)* All AEs AEs Grade ≥3 0.3 mg/kg N (%) N=6 0.6 mg/kg N (%) N=5 1.2 mg/kg N (%) N=6 Total N (%) N=17 0.3 mg/kg N (%) N=6 0.6 mg/kg N (%) N=5 1.2 mg/kg N (%) N=6 Total N (%) N=17 All AEs 5 (83) 5 (100) 6 (100) 16 (94) 5 (83) 5 (100) 6 (100) 16 (94) Neutropenia 4 (67) 5

  6. Slide 6: Other Results: Transfusions, SAEs and Performance Status

    Other Results Performance Status SAEs 0.3 mg/kg N=6 0.6 mg/kg N=5 1.2 mg/kg N=6 Total N=17 RBC transfusions (% of patients, N of transfusions) - 3 (60) 3 (50)* 6 (35) Platelet transfusions (% of patients, N of transfusions) - 2 (40) 1 (17) 3 (18) *One patient received multiple RBC transfusions with

Aileron Therapeutics — Corporate Update (June 2020) on 6ix